Gonorrhea

Last updated

Gonorrhea
Other namesGonorrhoea, gonococcal infection, gonococcal urethritis, the clap
Gonococcal lesion on the skin PHIL 2038 lores.jpg
Gonococcal lesion on the skin
Pronunciation
Specialty Infectious disease
Symptoms None, burning with urination, vaginal discharge, discharge from the penis, pelvic pain, testicular pain [1]
Complications Pelvic inflammatory disease, inflammation of the epididymis, septic arthritis, endocarditis [1] [2]
Causes Neisseria gonorrhoeae typically sexually transmitted [1]
Diagnostic method Testing the urine, urethra in males; vagina or cervix in females, throat, or rectum [1]
Prevention Condoms, having sex with only one person who is uninfected, not having sex [1] [3]
Treatment Ceftriaxone by injection and azithromycin by mouth [4] [5]
Frequency0.8% (women), 0.6% (men) [6]

Gonorrhoea or gonorrhea, colloquially known as the clap, [7] is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae . [8] Infection may involve the genitals, mouth, or rectum. [9] Infected males may experience pain or burning with urination, discharge from the penis, or testicular pain. [1] Infected females may experience burning with urination, vaginal discharge, vaginal bleeding between periods, or pelvic pain. [1] Complications in females include pelvic inflammatory disease and in males include inflammation of the epididymis. [1] Many of those infected, however, have no symptoms. [1] If untreated, gonorrhea can spread to joints or heart valves. [1] [2]

Contents

Gonorrhea is spread through sexual contact with an infected person. [1] This includes oral, anal, and vaginal sex. [1] It can also spread from a mother to a child during birth. [1] Diagnosis is by testing the urine, urethra in males, vagina or cervix in females. It can be diagnosed by testing a sample collected from the throat or rectum of individuals who have had oral or anal sex, respectively. [1] Testing all women who are sexually active and less than 25 years of age each year as well as those with new sexual partners is recommended; [3] the same recommendation applies in men who have sex with men (MSM). [3]

Gonorrhea can be prevented with the use of condoms, having sex with only one person who is uninfected, and by not having sex. [1] [3] Treatment is usually with ceftriaxone by injection and azithromycin by mouth. [4] [5] Resistance has developed to many previously used antibiotics and higher doses of ceftriaxone are occasionally required. [4] [5] Retesting is recommended three months after treatment. [3] Sexual partners from the last two months should also be offered treatment. [1]

Gonorrhea affects about 0.8% of women and 0.6% of men. [6] An estimated 33 to 106 million new cases occur each year, out of the 498 million new cases of curable STI – which also includes syphilis, chlamydia, and trichomoniasis. [10] [11] Infections in women most commonly occur when they are young adults. [3] In 2015, it caused about 700 deaths. [12] Descriptions of the disease date back to before the Common Era within the Hebrew Bible/Old Testament (Leviticus 15:2–3). [2] [ dubious – discuss ]. The current name was first used by the Greek physician Galen before AD 200 who referred to it as "an unwanted discharge of semen". [2]

Signs and symptoms

Gonorrhea infections of mucosal membranes can cause swelling, itching, pain, and the formation of pus. [13] The time from exposure to symptoms is usually between two and 14 days, with most symptoms appearing between four and six days after infection, if they appear at all. Both men and women with infections of the throat may experience a sore throat, though such infection does not produce symptoms in 90% of cases. [14] [15] Other symptoms may include swollen lymph nodes around the neck. [13] Either sex can become infected in the eyes or rectum if these tissues are exposed to the bacterium, [16] which can lead to pain with bowel movements, rectal discharge, or constipation. [17]

Women

Half of women with gonorrhea are asymptomatic but the other half experience vaginal discharge, lower abdominal pain, or pain with sexual intercourse associated with inflammation of the uterine cervix. [18] [19] [20] Common medical complications of untreated gonorrhea in women include pelvic inflammatory disease which can cause scars to the fallopian tubes and result in later ectopic pregnancy among those women who become pregnant. [21]

Men

Most infected men with symptoms have inflammation of the penile urethra associated with a burning sensation during urination and discharge from the penis. [19] In men, discharge with or without burning occurs in half of all cases and is the most common symptom of the infection. [22] This pain is caused by a narrowing and stiffening of the urethral lumen. [23] The most common medical complication of gonorrhea in men is inflammation of the epididymis. [21] Gonorrhea is also associated with increased risk of prostate cancer. [24]

Infants

An infant with gonorrhea of the eyes Gonococcal ophthalmia neonatorum.jpg
An infant with gonorrhea of the eyes

If not treated, gonococcal ophthalmia neonatorum will develop in 28% of infants born to women with gonorrhea. [25]

Spread

If left untreated, gonorrhea can spread from the original site of infection and infect and damage the joints, skin, and other organs. Indications of this can include fever, skin rashes, sores, and joint pain and swelling. [21] In advanced cases, gonorrhea may cause a general feeling of tiredness similar to other infections. [26] [22] It is also possible for an individual to have an allergic reaction to the bacteria, in which case any appearing symptoms will be greatly intensified. [22] Very rarely it may settle in the heart, causing endocarditis, or in the spinal column, causing meningitis. Both are more likely among individuals with suppressed immune systems, however. [15]

Cause

Neisseria gonorrhoeae in pus from a case of gonorrhoea in a man (Gram stain) Gram-stain of gonorrhoea.jpg
Neisseria gonorrhoeae in pus from a case of gonorrhoea in a man (Gram stain)
Gram-stained pus from a urethral discharge showing Gram-negative, intracellular diplococci Pus cells with intracellular gonococci.jpg
Gram-stained pus from a urethral discharge showing Gram-negative, intracellular diplococci

Gonorrhea is caused by the bacterium Neisseria gonorrhoeae . [19] Previous infection does not confer immunity – a person who has been infected can become infected again by exposure to someone who is infected. Infected persons may be able to infect others repeatedly without having any signs or symptoms of their own. [27]

Spread

The infection is usually spread from one person to another through vaginal, oral, or anal sex. [19] [28] Men have a 20% risk of getting the infection from a single act of vaginal intercourse with an infected woman. The risk for men who have sex with men (MSM) is higher. [29] Insertive MSM may get a penile infection from anal intercourse, while receptive MSM may get anorectal gonorrhea. Women have a 60–80% risk of getting the infection from a single act of vaginal intercourse with an infected man. [30]

A mother may transmit gonorrhea to her newborn during childbirth; when affecting the infant's eyes, it is referred to as ophthalmia neonatorum. [19] It may be able to spread through the objects contaminated with body fluid from an infected person. [31] The bacteria typically does not survive long outside the body, typically dying within minutes to hours. [32]

Risk factors

It is discovered that sexually active women younger than 25 and men who have sex with men are at increased risk of getting gonorrhea. [33]

Other risk factors include:

  • Having a new sex partner
  • Having a sex partner who has other partners
  • Having more than one sex partner
  • Having had gonorrhea or another sexually transmitted infection [34]

Complications

Untreated gonorrhea can lead to major complications, such as:

Diagnosis

Traditionally, gonorrhea was diagnosed with Gram stain and culture; however, newer polymerase chain reaction (PCR)-based testing methods are becoming more common. [20] [35] If initial treatment fails, a culture should be done to determine the sensitivity of the bacteria to antibiotics. [36]

Tests that use PCR (aka nucleic acid amplification) to identify genes unique to N. gonorrhoeae are recommended for screening and diagnosis of gonorrhea infection. These PCR-based tests require a sample of urine, urethral swabs, or cervical/vaginal swabs. Culture (growing colonies of bacteria in order to isolate and identify them) and Gram-stain (staining of bacterial cell walls to reveal morphology) can also be used to detect the presence of N. gonorrhoeae in all specimen types except urine. [37] [38] Studies of the swab sample method for gonorrhea infections have not shown any difference in the number of patients treated, whether the sample was collected at home or in the clinic. The implications for number of patients cured, reinfection rates, partner management, and safety are unknown. [39]

If Gram-negative, oxidase-positive diplococci are visualized on direct Gram stain of urethral pus (male genital infection), no further testing is needed to establish the diagnosis of gonorrhea infection. [40] [41] However, direct Gram stain of cervical swabs is not useful because the N. gonorrhoeae organisms are less concentrated in these samples. The chance of a false positive test is also higher for a cervical swab, as Gram-negative diplococci native to the normal vaginal flora cannot be distinguished from N. gonorrhoeae in that context. Thus, cervical swabs must be cultured under the conditions described above. If oxidase positive, Gram-negative diplococci are isolated from a culture of a cervical/vaginal swab specimen, then the diagnosis is made. Culture is especially useful for diagnosis of infections of the throat, rectum, eyes, blood, or joints—areas where PCR-based tests are not well established in all labs. [41] [42] Culture is also useful for antimicrobial sensitivity testing, analyzing treatment failure, and epidemiological purposes (outbreaks, surveillance). [41]

In patients who may have disseminated gonococcal infection (DGI), all possible mucosal sites should be cultured (e.g., pharynx, cervix, urethra, rectum). [42] Three sets of blood cultures should also be obtained. [43] Synovial fluid should be collected in cases of septic arthritis. [42]

All people testing positive for gonorrhea should be tested for other sexually transmitted infections such as chlamydia, syphilis, and human immunodeficiency virus. [36] Studies have found co-infection with chlamydia ranging from 46 to 54% in young people with gonorrhea. [44] [45] Among persons in the United States between 14 and 39 years of age, 46% of people with gonorrheal infection also have chlamydial infection. [46] For this reason, gonorrhea and chlamydia testing are often combined. [37] [47] [48] People diagnosed with gonorrhea infection have a fivefold increase risk of HIV transmission. [49] Additionally, infected persons who are HIV positive are more likely to shed and transmit HIV to uninfected partners during an episode of gonorrhea. [50]

Screening

The United States Preventive Services Task Force (USPSTF) recommends screening for gonorrhea in women at increased risk of infection, which includes all sexually active women younger than 25 years. Extragenital gonorrhea and chlamydia are highest in men who have sex with men (MSM). [51] Additionally, the USPSTF also recommends routine screening in people who have previously tested positive for gonorrhea or have multiple sexual partners and individuals who use condoms inconsistently, provide sexual favors for money, or have sex while under the influence of alcohol or drugs. [18]

Screening for gonorrhea in women who are (or intend to become) pregnant, and who are found to be at high risk for sexually transmitted infections, is recommended as part of prenatal care in the United States. [52]

Prevention

As with most sexually transmitted infections, the risk of infection can be reduced significantly by the correct use of condoms, not having sex, or can be removed almost entirely by limiting sexual activities to a mutually monogamous relationship with an uninfected person. [53] [54]

Those previously infected are encouraged to return for follow up care to make sure that the infection has been eliminated. In addition to the use of phone contact, the use of email and text messaging have been found to improve the re-testing for infection. [55]

Newborn babies coming through the birth canal are given erythromycin ointment in the eyes to prevent blindness from infection. The underlying gonorrhea should be treated; if this is done then usually a good prognosis will follow. [56]

Treatment

Antibiotics

Penicillin entered mass production in 1944 and revolutionized the treatment of several venereal diseases. PenicillinPSAedit.jpg
Penicillin entered mass production in 1944 and revolutionized the treatment of several venereal diseases.

Antibiotics are used to treat gonorrhea infections. As of 2016, both ceftriaxone by injection and azithromycin by mouth are most effective. [4] [57] [58] [59] However, due to increasing rates of antibiotic resistance, local susceptibility patterns must be taken into account when deciding on treatment. [36] [60] Ertapenem is a potential effective alternative treatment for ceftriaxone-resistant gonorrhea. [61] [62]

Adults may have eyes infected with gonorrhoea and require proper personal hygiene and medications. [56] Addition of topical antibiotics have not been shown to improve cure rates compared to oral antibiotics alone in treatment of eye infected gonorrhea. [63] For newborns, erythromycin ointment is recommended as a preventative measure for gonococcal infant conjunctivitis. [64]

Infections of the throat can be especially problematic, as antibiotics have difficulty becoming sufficiently concentrated there to destroy the bacteria. This is amplified by the fact that pharyngeal gonorrhoea is mostly asymptomatic, and gonococci and commensal Neisseria species can coexist for long time periods in the pharynx and share anti-microbial resistance genes. Accordingly, an enhanced focus on early detection (i.e., screening of high-risk populations, such as men who have sex with men, PCR testing should be considered) and appropriate treatment of pharyngeal gonorrhoea is important. [4]

Sexual partners

It is recommended that sexual partners be tested and potentially treated. [36] One option for treating sexual partners of people infected is patient-delivered partner therapy (PDPT), which involves providing prescriptions or medications to the person to take to his/her partner without the health care provider's first examining him/her. [65]

The United States' Centers for Disease Control and Prevention (CDC) currently recommend that individuals who have been diagnosed and treated for gonorrhea avoid sexual contact with others until at least one week past the final day of treatment in order to prevent the spread of the bacterium. [66]

Antibiotic resistance

Many antibiotics that were once effective including penicillin, tetracycline, and fluoroquinolones are no longer recommended because of high rates of resistance. [36] Resistance to cefixime has reached a level such that it is no longer recommended as a first-line agent in the United States, and if it is used a person should be tested again after a week to determine whether the infection still persists. [57] Public health officials are concerned that an emerging pattern of resistance may predict a global epidemic. [67] [68] In 2016, the WHO published new guidelines for treatment, stating "There is an urgent need to update treatment recommendations for gonococcal infections to respond to changing antimicrobial resistance (AMR) patterns of N. gonorrhoeae. High-level resistance to previously recommended quinolones is widespread and decreased susceptibility to the extended-spectrum (third-generation) cephalosporins, another recommended first-line treatment in the 2003 guidelines, is increasing and several countries have reported treatment failures." [69]

Prognosis

Disability-adjusted life year for gonorrhea per 100,000 inhabitants .mw-parser-output .col-begin{border-collapse:collapse;padding:0;color:inherit;width:100%;border:0;margin:0}.mw-parser-output .col-begin-small{font-size:90%}.mw-parser-output .col-break{vertical-align:top;text-align:left}.mw-parser-output .col-break-2{width:50%}.mw-parser-output .col-break-3{width:33.3%}.mw-parser-output .col-break-4{width:25%}.mw-parser-output .col-break-5{width:20%}@media(max-width:720px){.mw-parser-output .col-begin,.mw-parser-output .col-begin>tbody,.mw-parser-output .col-begin>tbody>tr,.mw-parser-output .col-begin>tbody>tr>td{display:block!important;width:100%!important}.mw-parser-output .col-break{padding-left:0!important}} .mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{} no data <13 13-26 26-39 39-52 52-65 65-78 78-91 91-104 104-117 117-130 130-143 >143 Gonorrhoea world map - DALY - WHO2004.svg
Disability-adjusted life year for gonorrhea per 100,000 inhabitants

Gonorrhea if left untreated may last for weeks or months with higher risks of complications. [19] One of the complications of gonorrhea is systemic dissemination resulting in skin pustules or petechia, septic arthritis, meningitis, or endocarditis. [19] This occurs in between 0.6 and 3% of infected women and 0.4 and 0.7% of infected men. [19]

In men, inflammation of the epididymis, prostate gland, and urethra can result from untreated gonorrhea. [70] In women, the most common result of untreated gonorrhea is pelvic inflammatory disease. Other complications include inflammation of the tissue surrounding the liver, [70] a rare complication associated with Fitz-Hugh–Curtis syndrome; septic arthritis in the fingers, wrists, toes, and ankles; septic abortion; chorioamnionitis during pregnancy; neonatal or adult blindness from conjunctivitis; and infertility. Men who have had a gonorrhea infection have an increased risk of getting prostate cancer. [24]

Epidemiology

Gonorrhea rates, United States, 1941-2007 Chart of gonorrhea infection rates (USA, 1941-2007).png
Gonorrhea rates, United States, 1941–2007

About 88 million cases of gonorrhea occur each year, out of the 448 million new cases of curable STI each year – that also includes syphilis, chlamydia and trichomoniasis. [11] The prevalence was highest in the African region, the Americas, and Western Pacific, and lowest in Europe. [71] In 2013, it caused about 3,200 deaths, up from 2,300 in 1990. [72]

In the United Kingdom, 196 per 100,000 males 20 to 24 years old and 133 per 100,000 females 16 to 19 years old were diagnosed in 2005. [19] In 2013, the CDC estimated that more than 820,000 people in the United States get a new gonorrheal infection each year. Fewer than half of these infections are reported to CDC. In 2011, 321,849 cases of gonorrhea were reported to the CDC. After the implementation of a national gonorrhea control program in the mid-1970s, the national gonorrhea rate declined from 1975 to 1997. After a small increase in 1998, the gonorrhea rate has decreased slightly since 1999. In 2004, the rate of reported gonorrheal infections was 113. 5 per 100,000 persons. [73]

In the US, it is the second-most-common bacterial sexually transmitted infections; chlamydia remains first. [74] [75] According to the CDC African Americans are most affected by gonorrhea, accounting for 69% of all gonorrhea cases in 2010. [76]

The World Health Organization warned in 2017 of the spread of untreatable strains of gonorrhea, following analysis of at least three cases in Japan, France and Spain, which survived all antibiotic treatment. [77]

History

During World War II, the U.S. government used posters to warn military personnel about the dangers of gonorrhea and other sexually transmitted infections. SheMayLookCleanBut.jpg
During World War II, the U.S. government used posters to warn military personnel about the dangers of gonorrhea and other sexually transmitted infections.

Some scholars translate the biblical terms zav (for a male, Hebrew : זָב) and zavah (for a female, זָבָה) as gonorrhea. [78]

It has been suggested[ by whom? ] that mercury was used as a treatment for gonorrhea.[ when? ] Surgeons' tools on board the recovered English warship the Mary Rose included a syringe that, according to some, was used to inject the mercury via the urinary meatus into crewmen with gonorrhea. The name "the clap", in reference to the disease, is recorded as early as the sixteenth century, referring to a medieval red-light district in Paris, Les Clapiers. Translating to "The rabbit holes", it was so named for the small huts in which prostitutes worked. [79] [60]

Silver nitrate was one of the widely used drugs in the 19th century. However, it became replaced by Protargol. Arthur Eichengrün invented this type of colloidal silver, which was marketed by Bayer from 1897 onward. The silver-based treatment was used until the first antibiotics came into use in the 1940s. [80] [81]

The exact time of onset of gonorrhea as prevalent disease or epidemic cannot be accurately determined from the historical record. One of the first reliable notations occurs in the Acts of the English Parliament which, in 1161, passed a law to reduce the spread of "the perilous infirmity of burning". [82] The symptoms described are consistent with, but not diagnostic of, gonorrhea. A similar decree was passed by Louis IX in France in 1256, replacing regulation with banishment. [83] Similar symptoms were noted at the siege of Acre by Crusaders.

Coincidental to, or dependent on, the appearance of a gonorrhea epidemic, several changes occurred in European medieval society. Cities hired public health doctors to treat affected patients without right of refusal. Pope Boniface VIII rescinded the requirement that physicians complete studies for the lower orders of the Catholic priesthood. [84]

Medieval public health physicians in the employ of their cities were required to treat prostitutes infected with the "burning", as well as lepers and other epidemic patients. [85] After Pope Boniface completely secularized the practice of medicine, physicians were more willing to treat a sexually transmitted infection. [84]

Research

A vaccine for gonorrhea has been developed that is effective in mice. [86] It will not be available for human use until further studies have demonstrated that it is both safe and effective in the human population. Development of a vaccine has been complicated by the ongoing evolution of resistant strains and antigenic variation (the ability of N. gonorrhoeae to disguise itself with different surface markers to evade the immune system). [60]

As N. gonorrhoeae is closely related to N. meningitidis and they have 80–90% homology in their genetic sequences some cross-protection by meningococcal vaccines is plausible. A study published in 2017 showed that MeNZB group B meningococcal vaccine provided a partial protection against gonorrhea. [87] The vaccine efficiency was calculated to be 31%. [88] In June 2023, GlaxoSmithKline won fast-track designation from the Food and Drug Administration for its vaccine candidate against gonorrhea. [89]

Related Research Articles

<span class="mw-page-title-main">Bacterial vaginosis</span> Excessive growth of bacteria in the vagina

Bacterial vaginosis (BV) is an infection of the vagina caused by excessive growth of bacteria. Common symptoms include increased vaginal discharge that often smells like fish. The discharge is usually white or gray in color. Burning with urination may occur. Itching is uncommon. Occasionally, there may be no symptoms. Having BV approximately doubles the risk of infection by a number of sexually transmitted infections, including HIV/AIDS. It also increases the risk of early delivery among pregnant women.

<span class="mw-page-title-main">Chlamydia</span> Sexually transmitted infection caused by the bacterium Chlamydia trachomatis

Chlamydia, or more specifically a chlamydia infection, is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis. Most people who are infected have no symptoms. When symptoms do appear they may occur only several weeks after infection; the incubation period between exposure and being able to infect others is thought to be on the order of two to six weeks. Symptoms in women may include vaginal discharge or burning with urination. Symptoms in men may include discharge from the penis, burning with urination, or pain and swelling of one or both testicles. The infection can spread to the upper genital tract in women, causing pelvic inflammatory disease, which may result in future infertility or ectopic pregnancy.

<span class="mw-page-title-main">Pelvic inflammatory disease</span> Infection of uterus, fallopian tubes, ovaries or the inner surface of pelvis

Pelvic inflammatory disease, also known as pelvic inflammatory disorder (PID), is an infection of the upper part of the female reproductive system, mainly the uterus, fallopian tubes, and ovaries, and inside of the pelvis. Often, there may be no symptoms. Signs and symptoms, when present, may include lower abdominal pain, vaginal discharge, fever, burning with urination, pain with sex, bleeding after sex, or irregular menstruation. Untreated PID can result in long-term complications including infertility, ectopic pregnancy, chronic pelvic pain, and cancer.

Urethritis is the inflammation of the urethra. The most common symptoms include painful or difficult urination and urethral discharge. It is a commonly treatable condition usually caused by infection with bacteria. This bacterial infection is often sexually transmitted, but not in every instance; it can be idiopathic, for example. Some incidence of urethritis can appear asymptomatic as well.

<i>Neisseria gonorrhoeae</i> Species of bacterium

Neisseria gonorrhoeae, also known as gonococcus (singular) or gonococci (plural), is a species of Gram-negative diplococci bacteria first isolated by Albert Neisser in 1879. An obligate human pathogen, it primarily colonizes the mucosal lining of the urogenital tract; however, it is also capable of adhering to the mucosa of the nose, pharynx, rectum, and conjunctiva. It causes the sexually transmitted genitourinary infection gonorrhea as well as other forms of gonococcal disease including disseminated gonococcemia, septic arthritis, and gonococcal ophthalmia neonatorum.

<span class="mw-page-title-main">Trichomoniasis</span> Medical condition

Trichomoniasis (trich) is an infectious disease caused by the parasite Trichomonas vaginalis. About 70% of affected people do not have symptoms when infected. When symptoms occur, they typically begin 5 to 28 days after exposure. Symptoms can include itching in the genital area, a bad smelling thin vaginal discharge, burning with urination, and pain with sex. Having trichomoniasis increases the risk of getting HIV/AIDS. It may also cause complications during pregnancy.

Nongonococcal urethritis (NGU) is inflammation of the urethra that is not caused by gonorrheal infection.

Vaginitis, also known as vulvovaginitis, is inflammation of the vagina and vulva. Symptoms may include itching, burning, pain, discharge, and a bad smell. Certain types of vaginitis may result in complications during pregnancy.

<span class="mw-page-title-main">Cervicitis</span> Inflammation of the uterine cervix

Cervicitis is inflammation of the uterine cervix. Cervicitis in women has many features in common with urethritis in men and many cases are caused by sexually transmitted infections. Non-infectious causes of cervicitis can include intrauterine devices, contraceptive diaphragms, and allergic reactions to spermicides or latex condoms. Cervicitis affects over half of all women during their adult life.

<i>Chlamydia trachomatis</i> Species of bacterium

Chlamydia trachomatis is a Gram-negative, anaerobic bacterium responsible for chlamydia and trachoma. C. trachomatis exists in two forms, an extracellular infectious elementary body (EB) and an intracellular non-infectious reticulate body (RB). The EB attaches to host cells and enter the cell using effector proteins, where it transforms into the metabolically active RB. Inside the cell, RBs rapidly replicate before transitioning back to EBs, which are then released to infect new host cells.

<span class="mw-page-title-main">Fitz-Hugh–Curtis syndrome</span> Medical condition

Fitz-Hugh–Curtis syndrome is a rare complication of pelvic inflammatory disease (PID) involving liver capsule inflammation leading to the formation of adhesions presenting with the clinical syndrome of right upper quadrant (RUQ) pain.

<span class="mw-page-title-main">Endometritis</span> Medical condition

Endometritis is inflammation of the inner lining of the uterus (endometrium). Symptoms may include fever, lower abdominal pain, and abnormal vaginal bleeding or discharge. It is the most common cause of infection after childbirth. It is also part of spectrum of diseases that make up pelvic inflammatory disease.

<span class="mw-page-title-main">Salpingitis</span> Inflammation of the fallopian tubes due to infection

Salpingitis is an infection causing inflammation in the fallopian tubes. It is often included in the umbrella term of pelvic inflammatory disease (PID), along with endometritis, oophoritis, myometritis, parametritis, and peritonitis.

<span class="mw-page-title-main">Vaginal discharge</span> Medical condition

Vaginal discharge is a mixture of liquid, cells, and bacteria that lubricate and protect the vagina. This mixture is constantly produced by the cells of the vagina and cervix, and it exits the body through the vaginal opening. The composition, amount, and quality of discharge varies between individuals and can vary throughout the menstrual cycle and throughout the stages of sexual and reproductive development. Normal vaginal discharge may have a thin, watery consistency or a thick, sticky consistency, and it may be clear or white in color. Normal vaginal discharge may be large in volume but typically does not have a strong odor, nor is it typically associated with itching or pain. While most discharge is considered physiologic or represents normal functioning of the body, some changes in discharge can reflect infection or other pathological processes. Infections that may cause changes in vaginal discharge include vaginal yeast infections, bacterial vaginosis, and sexually transmitted infections. The characteristics of abnormal vaginal discharge vary depending on the cause, but common features include a change in color, a foul odor, and associated symptoms such as itching, burning, pelvic pain, or pain during sexual intercourse.

<span class="mw-page-title-main">Neonatal conjunctivitis</span> Medical condition

Neonatal conjunctivitis is a form of conjunctivitis which affects newborn babies following birth. It is typically due to neonatal bacterial infection, although it can also be non-infectious. Infectious neonatal conjunctivitis is typically contracted during vaginal delivery from exposure to bacteria from the birth canal, most commonly Neisseria gonorrhoeae or Chlamydia trachomatis.

<span class="mw-page-title-main">Sexually transmitted infection</span> Infection transmitted through human sexual behavior

A sexually transmitted infection (STI), also referred to as a sexually transmitted disease (STD) and the older term venereal disease (VD), is an infection that is spread by sexual activity, especially vaginal intercourse, anal sex, oral sex, or sometimes manual sex. STIs often do not initially cause symptoms, which results in a risk of transmitting them on to others. The term sexually transmitted infection is generally preferred over sexually transmitted disease or venereal disease, as it includes cases with no symptomatic disease. Symptoms and signs of STIs may include vaginal discharge, penile discharge, ulcers on or around the genitals, and pelvic pain. Some STIs can cause infertility.

Female genital disease is a disorder of the structure or function of the female reproductive system that has a known cause and a distinctive group of symptoms, signs, or anatomical changes. The female reproductive system consists of the ovaries, fallopian tubes, uterus, vagina, and vulva. Female genital diseases can be classified by affected location or by type of disease, such as malformation, inflammation, or infection.

<span class="mw-page-title-main">Gonococcemia</span> Medical condition

Gonococcemia is a rare complication of mucosal Neisseria gonorrhoeae infection, or Gonorrhea, that occurs when the bacteria invade the bloodstream. It is characterized by fever, tender hemorrhagic pustules on the extremities or the trunk, migratory polyarthritis, and tenosynovitis. It also rarely leads to endocarditis and meningitis. This condition occurs in 0.5-3% of individuals with gonorrhea, and it usually presents 2–3 weeks after acquiring the infection. Risk factors include female sex, sexual promiscuity, and infection with resistant strains of Neisseria gonorrhoeae. This condition is treated with cephalosporin and fluoroquinolone antibiotics.

<span class="mw-page-title-main">Antibiotic resistance in gonorrhea</span>

Neisseria gonorrhoeae, the bacterium that causes the sexually transmitted infection gonorrhea, has developed antibiotic resistance to many antibiotics. The bacteria was first identified in 1879.

Gonorrhoea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Gonorrhea – CDC Fact Sheet (Detailed Version)". CDC. 17 November 2015. Archived from the original on 2 September 2016. Retrieved 27 August 2016.
  2. 1 2 3 4 Morgan MK, Decker CF (August 2016). "Gonorrhea". Disease-a-Month. 62 (8): 260–268. doi:10.1016/j.disamonth.2016.03.009. PMID   27107780.
  3. 1 2 3 4 5 6 Workowski KA, Bolan GA (June 2015). "Sexually transmitted diseases treatment guidelines, 2015". MMWR. Recommendations and Reports. 64 (RR-03): 1–137. PMC   5885289 . PMID   26042815.
  4. 1 2 3 4 5 "Antibiotic-Resistant Gonorrhea Basic Information". CDC. 13 June 2016. Archived from the original on 8 September 2016. Retrieved 27 August 2016.
  5. 1 2 3 Unemo M (August 2015). "Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge". BMC Infectious Diseases. 15: 364. doi: 10.1186/s12879-015-1029-2 . PMC   4546108 . PMID   26293005.
  6. 1 2 Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. (8 December 2015). "Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting". PLOS ONE. 10 (12): e0143304. Bibcode:2015PLoSO..1043304N. doi: 10.1371/journal.pone.0143304 . PMC   4672879 . PMID   26646541.
  7. ↑ "Clap". Cambridge Dictionary. Cambridge University Press. Retrieved 8 December 2024.
  8. ↑ "Gonorrhoea (Neisseria gonorrhoeae infection)". www.who.int. Retrieved 8 December 2024.
  9. ↑ Delong L, Burkhart N (27 November 2017). General and Oral Pathology for the Dental Hygienist. Wolters Kluwer Health. p. 787. ISBN   978-1-4963-5453-2.
  10. ↑ Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. (Global Burden of Disease Study 2013 Collaborators) (August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 386 (9995): 743–800. doi:10.1016/s0140-6736(15)60692-4. PMC   4561509 . PMID   26063472.
  11. 1 2 Emergence of multi-drug resistant Neisseria gonorrhoeae (PDF) (Report). World Health Organization. 2012. p. 2. Archived from the original (PDF) on 13 June 2013.
  12. ↑ Wang, Haidong; et al. (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC   5388903 . PMID   27733281.
  13. 1 2 "Gonorrhea - Symptoms and causes". Mayo Clinic. Retrieved 6 August 2019.
  14. ↑ Zakher B, Cantor AG, Pappas M, Daeges M, Nelson HD (December 2014). "Screening for gonorrhea and Chlamydia: a systematic review for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 161 (12): 884–893. CiteSeerX   10.1.1.691.6232 . doi:10.7326/M14-1022. PMID   25244000. S2CID   207538182.
  15. 1 2 Marr L (2007) [1998]. Sexually Transmitted Diseases: A Physician Tells You What You Need to Know (Second ed.). Baltimore, Maryland: Johns Hopkins University. ISBN   978-0-8018-8658-4.
  16. ↑ "Detailed STD Facts - Gonorrhea". www.cdc.gov. 5 April 2022. Retrieved 23 April 2022.
  17. ↑ Keshvani, Neil; Gupta, Arjun; Incze, Michael A. (1 January 2019). "I Am Worried About Gonorrhea: What Do I Need to Know?". JAMA Internal Medicine. 179 (1): 132. doi: 10.1001/jamainternmed.2018.4345 . PMID   30398526.
  18. 1 2 Smith L, Angarone MP (November 2015). "Sexually Transmitted Infections". The Urologic Clinics of North America. 42 (4): 507–518. CiteSeerX   10.1.1.590.3827 . doi:10.1016/j.ucl.2015.06.004. PMID   26475947. S2CID   37727850.
  19. 1 2 3 4 5 6 7 8 9 Moran JS (March 2007). "Gonorrhoea". BMJ Clinical Evidence. 2007. PMC   2943790 . PMID   19454057.
  20. 1 2 Ljubin-Sternak S, Meštrović T (2014). "Chlamydia trachomatis and Genital Mycoplasmas: Pathogens with an Impact on Human Reproductive Health". Journal of Pathogens. 2014 (183167): 183167. doi: 10.1155/2014/183167 . PMC   4295611 . PMID   25614838.
  21. 1 2 3 "What Complications Can Gonorrhea Cause?". WebMD. 2019.
  22. 1 2 3 Shmaefsky BR (1 January 2009). Gonorrhea. Infobase. p. 52. ISBN   978-1-4381-0142-2.
  23. ↑ Cheng L, Bostwick DG (24 January 2014). Urologic Surgical Pathology E-Book. Elsevier Health Sciences. p. 863. ISBN   978-0-323-08619-6.
  24. 1 2 Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A (August 2014). "Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis". Cancer Epidemiology. 38 (4): 329–338. doi:10.1016/j.canep.2014.06.002. PMID   24986642.
  25. ↑ "Prophylaxis for Gonococcal and Chlamydial Ophthalmia Neonatorum in the Canadian Guide to Clinical Preventative Health Care" (PDF). Public Health Agency of Canada. Archived from the original (PDF) on 10 March 2010.
  26. 1 2 "Complications from gonorrhea". stanfordhealthcare.org. Retrieved 25 April 2022.
  27. 1 2 "Gonorrhea - Symptoms and causes". Mayo Clinic. Retrieved 23 April 2022.
  28. ↑ Trebach JD, Chaulk CP, Page KR, Tuddenham S, Ghanem KG (May 2015). "Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures". Sexually Transmitted Diseases. 42 (5): 233–239. doi:10.1097/OLQ.0000000000000248. PMC   4672628 . PMID   25868133.
  29. ↑ Howard Brown Health Center: STI Annual Report, 2009
  30. ↑ National Institute of Allergy and Infectious Diseases; National Institutes of Health, Department of Health and Human Services (20 July 2001). "Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention". Hyatt Dulles Airport, Herndon, Virginia. pp14
  31. ↑ Goodyear-Smith F (November 2007). "What is the evidence for non-sexual transmission of gonorrhoea in children after the neonatal period? A systematic review". Journal of Forensic and Legal Medicine. 14 (8): 489–502. doi:10.1016/j.jflm.2007.04.001. PMID   17961874.
  32. ↑ Shmaefsky BR (1 January 2009). Gonorrhea. Infobase. p. 48. ISBN   978-1-4381-0142-2.
  33. ↑ Holmes KK (1984). Sexually transmitted diseases. McGraw-Hill. OCLC   644578106.
  34. ↑ "A Randomized, Controlled Trial of inSPOT and Patient-Delivered Partner Therapy for Gonorrhea and Chlamydial Infection Among Men Who Have Sex With Men". Sexually Transmitted Diseases. 40 (5): 432. May 2013. doi: 10.1097/olq.0b013e31829349ec . ISSN   0148-5717.
  35. ↑ Barry PM, Klausner JD (March 2009). "The use of cephalosporins for gonorrhea: the impending problem of resistance". Expert Opinion on Pharmacotherapy. 10 (4): 555–577. doi:10.1517/14656560902731993. PMC   2657229 . PMID   19284360.
  36. 1 2 3 4 5 Deguchi T, Nakane K, Yasuda M, Maeda S (September 2010). "Emergence and spread of drug resistant Neisseria gonorrhoeae". The Journal of Urology. 184 (3): 851–8, quiz 1235. doi:10.1016/j.juro.2010.04.078. PMID   20643433.
  37. 1 2 "Final Recommendation Statement: Chlamydia and Gonorrhea: Screening – US Preventive Services Task Force". uspreventiveservicestaskforce.org. Retrieved 7 December 2017.
  38. ↑ "Gonococcal Infections – 2015 STD Treatment Guidelines". cdc.gov. Retrieved 7 December 2017.
  39. ↑ Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, Angel-Müller E, Rincon C, Gaitán HG, Low N, et al. (Cochrane STI Group) (September 2015). "Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections". The Cochrane Database of Systematic Reviews. 2015 (9): CD011317. doi:10.1002/14651858.CD011317.pub2. PMC   8666088 . PMID   26418128.
  40. ↑ Levinson W (1 July 2014). Review of medical microbiology and immunology (Thirteenth ed.). New York. ISBN   9780071818117. OCLC   871305336.{{cite book}}: CS1 maint: location missing publisher (link)
  41. 1 2 3 Ng LK, Martin IE (January 2005). "The laboratory diagnosis of Neisseria gonorrhoeae". The Canadian Journal of Infectious Diseases & Medical Microbiology. 16 (1): 15–25. doi: 10.1155/2005/323082 . PMC   2095009 . PMID   18159523.
  42. 1 2 3 https://www.cdc.gov/std/tg2015/clinical.htm section on prevention methods
  43. ↑ Gonorrhea~overview at eMedicine
  44. ↑ Kahn RH, Mosure DJ, Blank S, Kent CK, Chow JM, Boudov MR, et al. (April 2005). "Chlamydia trachomatis and Neisseria gonorrhoeae prevalence and coinfection in adolescents entering selected US juvenile detention centers, 1997-2002". Sexually Transmitted Diseases. 32 (4): 255–259. doi: 10.1097/01.olq.0000158496.00315.04 . PMID   15788927. S2CID   20864079.
  45. ↑ Dicker LW, Mosure DJ, Berman SM, Levine WC (May 2003). "Gonorrhea prevalence and coinfection with chlamydia in women in the United States, 2000". Sexually Transmitted Diseases. 30 (5): 472–476. doi: 10.1097/00007435-200305000-00016 . PMID   12916141. S2CID   39361152.
  46. ↑ Datta SD, Sternberg M, Johnson RE, Berman S, Papp JR, McQuillan G, Weinstock H (July 2007). "Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002". Annals of Internal Medicine. 147 (2): 89–96. doi:10.7326/0003-4819-147-2-200707170-00007. PMID   17638719. S2CID   16507728.
  47. ↑ "Gonococcal Infections - 2015 STD Treatment Guidelines". 4 January 2018.
  48. ↑ Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN   978-0-8385-8529-0.[ page needed ]
  49. ↑ Department of Reproductive Health and Research (2011). "Emergence of multi-drug resistant Neisseria gonorrhoeae – Threat of global rise in untreatable sexually transmitted infections" (PDF). FactSheet WHO/RHR/11.14. World Health Organization.
  50. ↑ "Gonorrhea – STD information from CDC". cdc.gov. 6 October 2017. Retrieved 5 December 2017.
  51. ↑ Meyers D, Wolff T, Gregory K, Marion L, Moyer V, Nelson H, et al. (March 2008). "USPSTF recommendations for STI screening". American Family Physician. 77 (6): 819–824. PMID   18386598.
  52. ↑ Health Care Guideline: Routine Prenatal Care. Fourteenth Edition. Archived 5 July 2008 at the Wayback Machine By the Institute for Clinical Systems Improvement July 2010.
  53. ↑ section: Prevention Archived 20 July 2013 at the Wayback Machine
  54. ↑ section: How can gonorrhea be prevented? Archived 16 December 2016 at the Wayback Machine
  55. ↑ Desai M, Woodhall SC, Nardone A, Burns F, Mercey D, Gilson R (August 2015). "Active recall to increase HIV and STI testing: a systematic review". Sexually Transmitted Infections. 91 (5): 314–323. doi: 10.1136/sextrans-2014-051930 . PMID   25759476.
  56. 1 2 Sadowska-Przytocka A, Czarnecka-Operacz M, Jenerowicz D, Grzybowski A (2016). "Ocular manifestations of infectious skin diseases". Clinics in Dermatology. 34 (2): 124–128. doi:10.1016/j.clindermatol.2015.11.010. PMID   26903179.
  57. 1 2 Centers for Disease Control Prevention (CDC) (August 2012). "Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections". MMWR. Morbidity and Mortality Weekly Report. 61 (31): 590–594. PMID   22874837.
  58. ↑ "Antibiotic-resistant gonorrhoea on the rise, new drugs needed". World Health Organization. 7 July 2017. Archived from the original on 9 July 2017. Retrieved 10 July 2017.
  59. ↑ Sánchez-Busó L, Golparian D, Corander J, Grad YH, Ohnishi M, Flemming R, et al. (November 2019). "The impact of antimicrobials on gonococcal evolution". Nature Microbiology. 4 (11): 1941–1950. doi:10.1038/s41564-019-0501-y. PMC   6817357 . PMID   31358980.
  60. 1 2 3 Baarda BI, Sikora AE (2015). "Proteomics of Neisseria gonorrhoeae: the treasure hunt for countermeasures against an old disease". Frontiers in Microbiology. 6: 1190. doi: 10.3389/fmicb.2015.01190 . PMC   4620152 . PMID   26579097.
  61. ↑ de Vries HJ, de Laat M, Jongen VW, Heijman T, Wind CM, Boyd A, et al. (May 2022). "Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial". The Lancet. Infectious Diseases. 22 (5): 706–717. doi:10.1016/S1473-3099(21)00625-3. PMID   35065063. S2CID   246129045.
  62. ↑ "Antibiotic Ertapenem is alternative drug in treatment of gonorrhea". Amsterdam UMC. 20 January 2022. Retrieved 8 July 2022.
  63. ↑ Epling J (February 2012). "Bacterial conjunctivitis". BMJ Clinical Evidence. 2012. PMC   3635545 . PMID   22348418.
  64. ↑ Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. (January 2019). "Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: US Preventive Services Task Force Reaffirmation Recommendation Statement". JAMA. 321 (4): 394–398. doi: 10.1001/jama.2018.21367 . PMID   30694327.
  65. ↑ "Expedited partner therapy in the management of sexually transmitted diseases" Archived 2 November 2009 at the Wayback Machine . February 2006. Centers for Disease Control and Prevention (CDC).
  66. ↑ "Gonorrhea – CDC Fact Sheet". U.S. Centers for Disease Control and Prevention. 14 July 2014. Archived from the original on 16 December 2016. Retrieved 17 October 2014.
  67. ↑ Groopman J (1 October 2012). "Sex and the Superbug". The New Yorker. Vol. LXXXVIII, no. 30. pp. 26–31. Archived from the original on 9 October 2012. Retrieved 13 October 2012. ...public-health experts [see]...the emergence of a strain of gonorrhea that is resistant to the last drug available against it, and the harbinger of a sexually transmitted global epidemic.
  68. ↑ Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S, et al. (June 2022). "Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022". Euro Surveillance. 27 (24). doi:10.2807/1560-7917.ES.2022.27.24.2200455. PMC   9205165 . PMID   35713023. S2CID   249747652.
  69. ↑ "WHO guidelines for the treatment of Neisseria gonorrhoeae". World Health Organization. 2016. Retrieved 24 September 2020.
  70. 1 2 Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; & Mitchell, Richard N. (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. pp. 705–706 ISBN   978-1-4160-2973-1
  71. ↑ Kirkcaldy RD, Weston E, Segurado AC, Hughes G (September 2019). "Epidemiology of gonorrhoea: a global perspective". Sexual Health. 16 (5). United States National Library of Medicine: 401–411. doi:10.1071/SH19061. PMC   7064409 . PMID   31505159.
  72. ↑ "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–171. January 2015. doi:10.1016/s0140-6736(14)61682-2. PMC   4340604 . PMID   25530442.
  73. ↑ "Gonorrhea – CDC Fact Sheet". CDC. 29 May 2012. Archived from the original on 16 December 2016. Retrieved 20 December 2013.
  74. ↑ "CDC – STD Surveillance – Gonorrhea". Archived from the original on 6 March 2008. Retrieved 21 August 2008.
  75. ↑ "CDC Fact Sheet – Chlamydia". Archived from the original on 16 December 2016. Retrieved 21 August 2008.
  76. ↑ "STD Trends in the United States: 2010 National Data for Gonorrhea, Chlamydia, and Syphilis". Centers for Disease Control and Prevention (CDC). 22 November 2010. Archived from the original on 24 January 2012.
  77. ↑ "Untreatable gonorrhoea 'superbug' spreading around world, WHO warns". The Daily Telegraph. 7 July 2017. Archived from the original on 7 July 2017.
  78. ↑ "Daf Parashat Hashavua". Archived from the original on 3 October 2012. Retrieved 2 November 2012.
  79. ↑ Higgins J (1587). The Mirror for Magistrates. as cited in the Oxford English Dictionary entry for "clap".
  80. ↑ Bender M (1898). "Ueber neuere Antigonorrhoica (insbes. Argonin und Protargol)". Archives of Dermatological Research. 43 (1): 31–36. doi:10.1007/BF01986890. S2CID   45492365.
  81. ↑ MedlinePlus Encyclopedia : Neonatal Conjunctivitis
  82. ↑ Sanger W (1910). History of Prostitution. New York: Harper.
  83. ↑ LaCroix P (1931). The History of Prostitution. Vol. 2. New York: MacMillan.
  84. 1 2 Moen J, Bivens L (2017). Basic Healthcare Studies: Sexually Transmitted Disease. Alpha Editions. ISBN   9789386367570.
  85. ↑ Leiky WE (1926). History of European Morals. New York: MacMillan.
  86. ↑ Jerse AE, Bash MC, Russell MW (March 2014). "Vaccines against gonorrhea: current status and future challenges". Vaccine. 32 (14): 1579–1587. doi:10.1016/j.vaccine.2013.08.067. PMC   4682887 . PMID   24016806.
  87. ↑ Gottlieb SL, Johnston C (February 2017). "Future prospects for new vaccines against sexually transmitted infections". Current Opinion in Infectious Diseases. 30 (1): 77–86. doi:10.1097/QCO.0000000000000343. PMC   5325242 . PMID   27922851.
  88. ↑ Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S (September 2017). "Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study". Lancet. 390 (10102): 1603–1610. doi:10.1016/S0140-6736(17)31449-6. PMID   28705462. S2CID   4230156.
  89. ↑ "GSK's gonorrhoea vaccine receives FDA's 'fast-track' designation". Reuters . 27 June 2023. Retrieved 20 August 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.